Precision medicine biotech company H3 Biomedicine Inc. announced last week a partnership with Flatiron Health, and Foundation Medicine to use of real-world data in its research and development potential new, targeted cancer drugs.
“The valuable insights we derive from our unique real-world data set can play a pivotal role in helping biopharma leaders like H3 accelerate research and development and bring potentially breakthrough precision medicine options to more cancer patients,” said Brian Alexander, M.D., chief medical officer at Foundation Medicine in a press release.
The partnership, whose value was not disclosed, will leverage the real-world clinic-genomic database developed by Flatiron and Foundation Medicine, called CGDB, for both the potential identification of new therapeutic targets as well as help inform the design of future clinical trials. The database was built by combining data Foundation Medicine has collected from patients who have undergone comprehensive genomic profiling (CGP) with the patient clinical outcomes data from the Flatiron Health clinical provider network.
“The CGDB complements H3’s expertise in cancer genomics. We already reap the benefits of our longstanding data partnership with Foundation Medicine and this agreement is a natural extension,” said Lihua Yu, Ph.D., president and chief data Ssience officer of H3 in a press release. “We are hopeful that our collaboration with Flatiron Health and Foundation Medicine will help to accelerate the development of new precision medicines for individuals living with cancer.”
H3, a precision medicine research & development subsidiary of Eisai Co., Ltd., will also subscribe to Flatiron’s longitudinal, de-identified real-world dataset specific to breast cancer.
“We’re very excited to be part of H3’s innovative, data-driven approach to precision oncology research,” said Michael Vasconcelles, M.D., Chief Medical Officer at Flatiron Health. “Pairing Flatiron’s clinical data with Foundation Medicine’s CGP data can support important insights at all stages of the cancer medicine development lifecycle.”
